Evidence map›Paper›PMID 42116738›Full record

ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2026

Ofatumumab and enteroviral encephalitis: a severe infectious complication as a class effect with anti-CD20 therapies.

Dalia L Rotstein, Sheliza Halani, Peter Vadas, James J Marriott

Abstract read
PubMed Publisher
In one paragraph

Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Dalia L RotsteinDepartment of Medicine, University of Toronto, Toronto, ON, Canada; St. Michael's Hospital, Unity Health Toronto, Toronto, ON, Canada.ORCID 0000-0002-7280-3684
Sheliza HalaniDepartment of Medicine, University of Toronto, Toronto, ON, Canada; St. Michael's Hospital, Unity Health Toronto, Toronto, ON, Canada.
Peter VadasDepartment of Medicine, University of Toronto, Toronto, ON, Canada; St. Michael's Hospital, Unity Health Toronto, Toronto, ON, Canada.
James J MarriottDepartment of Medicine, University of Toronto, Toronto, ON, Canada; St. Michael's Hospital, Unity Health Toronto, Toronto, ON, Canada.ORCID 0000-0001-5491-0569

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEnteroviral encephalitis is a rare but potentially devastating infectious complication described under the anti-CD20 therapies rituximab and ocrelizumab. CASE: A 37-year-old woman with multiple sclerosis (MS) on treatment with ofatumumab developed fever, confusion, seizures, and decreased level of consciousness. Magnetic resonance imaging (MRI) revealed bilateral, non-enhancing thalamic T2 hyperintensities, and cerebrospinal fluid showed pleocytosis with positive polymerase chain reaction (PCR) for enterovirus. The patient was treated with intravenous immunoglobulin and supportive care, and then pocapavir was given for ongoing neurologic deficits. She recovered over 6 weeks but continued to demonstrate neuropsychiatric symptoms.

conclusionEnteroviral encephalitis is associated with anti-CD20 therapies for MS as a class effect including ofatumumab.

Indexed as

anti-CD20 therapyencephalitisenterovirusOfatumumab

Identifiers

PMID42116738

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.